Evoke Pharma Inc.
11/04/2025 | Press release | Distributed by Public on 11/04/2025 06:14
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person Filing Statement) (Form SC14D9C)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
EVOKE PHARMA, INC.
(Name of Subject Company)
EVOKE PHARMA, INC.
(Name of Person Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
30049G302
(CUSIP Number of Class of Securities)
Matthew D'Onofrio
Chief Executive Officer
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, California 92075
(858) 345-1494
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Daniel E. Rees
Matthew T. Bush
Anthony A. Gostanian
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, California 92130
(858) 523-5400
| ☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 5.02, 8.01 and 9.01 of the Current Report on Form 8-K filed by Evoke Pharma, Inc. on November 4, 2025 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.
Evoke Pharma Inc. published this content on November 04, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 04, 2025 at 12:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]